A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of KLA478 in Healthy Volunteers
Latest Information Update: 03 Mar 2026
At a glance
- Drugs KLA 478 (Primary) ; Pramipexole
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Hunan Kelun Pharmaceutical
Most Recent Events
- 27 Feb 2026 Status changed from not yet recruiting to recruiting.
- 28 Nov 2025 New trial record